![]() If possible, the Roche-ECLIA with the highest sensitivity is suggested as a second screening assay in primary labs. Based on these findings, we put forward a proper test strategy for HTLV-1/2 diagnosis in low-prevalence areas. Besides, 3 WB indeterminate and 1 LIA-untyped samples were confirmed as HTLV-1 positive by qPCR. 27), but was able to resolve infection status of some individuals with an indeterminate WB. In addition, LIA yield more indeterminate and HTLV-untyped results than WB (152 vs. Roche-ECLIA showed the highest sensitivity that was able to detect 91.8% positives and combined with the Murex-ELISA would significantly increase the positive detection rate (98.4%). All the WB-positive samples were also LIA-positive. The results showed that 48 samples were finally confirmed as HTLV-1 positive, 13 were HTLV positive, 151 were indeterminate, and 387 were negative. Positive or indeterminate specimens with blood available were quantified by qPCR. Avioq-ELISA, Murex-ELISA, Roche-ECLIA and Fujirebio-CLIA were independently performed on each plasma sample and compared to WB and LIA confirmatory tests. At the present study, 1546 specimens repeatedly reactive (RR) by one screening ELISA were collected from blood centers/banks from January 2016 to April 2019. The aim of this study was to evaluate the performance of four HTLV-1/2 screening assays and to discuss a strategy for diagnosis of HTLV-1/2 infection in a non-endemic area. Serological tests have been widely used for detecting human T-cell lymphotropic virus type 1/2 (HTLV-1/2) antibodies in the endemic areas, but their performance in low-risk populations is rarely reported. 3Graduate School, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.2Beijing Engineering Research Center of Laboratory Medicine, Beijing Hospital, Beijing, China.1National Center for Clinical Laboratories, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.Huimin Ji 1,2,3, Le Chang 1,2, Ying Yan 1,2, Xinyi Jiang 1,2,3, Huizhen Sun 1,2,3, Fei Guo 1,2 and Lunan Wang 1,2,3* ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |